Mechanisms of Shear Induction of Blood-Brain Barrier Phenotypes in Human iPSC-derived Brain Endothelial Progenitors

人 iPSC 来源的脑内皮祖细胞血脑屏障表型的剪切诱导机制

基本信息

  • 批准号:
    10557176
  • 负责人:
  • 金额:
    $ 33.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-02-15 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

The blood-brain barrier (BBB) represents a physical, transport, and metabolic barrier between the bloodstream and the brain and its function is crucial to maintain brain homeostasis. BBB dysfunction is a hallmark of many neurological diseases and disorders. Moreover, the BBB prevents treatment of central nervous system diseases by limiting brain uptake of small molecule and protein-based pharmaceuticals. In vitro models of the BBB provide tools to understand BBB structure and function during development and disease and facilitate discovery of strategies to delivery pharmaceuticals to the brain. Established in vitro BBB models often lack key physiologic phenotypes of the in vivo BBB, however, limiting their utility. Previously, we described a defined method for directed differentiation of human induced pluripotent stem cells (iPSCs) to brain microvascular endothelial cells (BMECs) that comprise the BBB. These iPSC-BMECs express BBB-specific markers and exhibit barrier and transporter properties similar to those in the BBB in vivo, albeit at reduced levels. Our preliminary data demonstrate that application of shear flow to iPSC-BMEC progenitors induces BBB phenotypes in a p21 and TGFβ signaling pathway dependent manner. These data motivate our central hypothesis: Shear stress enhances development and maintenance of BBB barrier and transporter phenotypes in iPSC-BMEC progenitors via p21 and TGFβ signaling. To test this hypothesis, we will apply shear flow to iPSCs differentiating to BMECs at different stages of development and quantify effects of shear stress on BBB barrier and transporter phenotypes in the resulting BMECs. We will employ genetic and biochemical inhibitors to elucidate the roles of p21 and TGFβ pathway induction of BBB phenotypes. Based on these fundamental studies, we will construct isogenic, neurovascular unit (NVU) models comprised of shear-conditioned iPSC- derived BMECs, neurons, astrocytes and pericytes that will enable a better understanding of human BBB development and disease and facilitate neurotherapeutic development. Our specific aims are: 1. Quantify the effects of shear stress applied to iPSC-BMEC progenitors on induction of BBB phenotypes. We will assess the developmental stages at which shear induces barrier and transporter phenotypes in differentiating iPSC-BMECs. 2. Elucidate the roles of p21 and TGFβ signaling in shear-mediated induction of BBB phenotypes in iPSC- BMEC progenitors. We will employ chemical and genetic inhibition of p21 and TGFβ pathways to test the necessity of these pathways in shear induction of BBB phenotypes in iPSC-BMEC progenitors. 3. Evaluate shear-conditioned iPSC-BMECs in contact and noncontact isogenic neurovascular unit models. We will construct NVU models consisting of iPSC-BMECs differentiated in the presence of shear, and iPSC-derived neurons, astrocytes, and pericytes, to test the hypothesis that shear application to iPSC- BMEC progenitors will yield a high-fidelty NVU model with enhanced, sustained BBB phenotypes.
血脑屏障(Bbb)代表血流之间的物理、运输和代谢屏障。 而大脑及其功能对维持大脑的动态平衡至关重要。血脑屏障功能障碍是许多 神经系统疾病和障碍。此外,血脑屏障还可以预防中枢神经系统疾病的治疗。 通过限制大脑对小分子和蛋白质类药物的摄取。血脑屏障的体外模型提供了 了解BBB在发育和疾病过程中的结构和功能的工具,并促进发现 将药物输送到大脑的策略。已建立的体外血脑屏障模型往往缺乏关键的生理功能 然而,体内血脑屏障的表型限制了它们的用途。在此之前,我们描述了一种定义的方法 人诱导多能干细胞定向分化为脑微血管内皮细胞 (BMEC)组成BBB。这些IPSC-BMEC表达BBB特异性标记,并表现出屏障和 转运蛋白的性质类似于体内的血脑屏障,尽管水平降低。我们的初步数据 证明应用剪切流对IPSC-BMEC前体细胞诱导p21和bbb表型 转化生长因子β信号通路依赖方式。这些数据激发了我们的中心假设:剪切力 增强IPSC-BMEC血脑屏障和转运体表型的发育和维持 前体细胞通过p21和转化生长因子β信号转导。为了验证这一假设,我们将剪切流应用于IPSC 不同发育阶段BMEC的分化及切应力对BBB屏障的影响 和转运蛋白表型。我们将使用遗传和生化抑制物来 阐明p21和转化生长因子β途径诱导血脑屏障表型的作用。在这些基础研究的基础上, 我们将构建等基因神经血管单位(NVU)模型,包括剪切条件下的IPSC- 衍生的骨髓微血管内皮细胞、神经元、星形胶质细胞和周细胞,将使更好地了解人类的血脑屏障 发展和疾病,并促进神经治疗的发展。我们的具体目标是: 1.量化施加于IPSC-BMEC祖细胞的剪切力对BBB表型诱导的影响。 我们将评估在不同发育阶段剪切力诱导的屏障和转运蛋白表型。 IPSC-BMEC的分化。 2.阐明p21和转化生长因子β信号在剪切法诱导IPSC-BBB表型中的作用。 BMEC的祖细胞。我们将使用化学和遗传抑制p21和转化生长因子β途径来测试 这些途径在IPSC-BMEC祖细胞BBB表型剪切诱导中的必要性。 3.在接触性和非接触性等基因神经血管单位模型中评价剪切条件下的IPSC-BMECs。 我们将构建由剪切作用下分化的IPSC-BMEC组成的NVU模型,并 IPSC来源的神经元、星形胶质细胞和周细胞,以检验剪切应用于IPSC- BMEC的前体细胞将产生高保真的NVU模型,具有增强的、持续的BBB表型。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sean P Palecek其他文献

Sean P Palecek的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sean P Palecek', 18)}}的其他基金

Label-free single-cell imaging for quality control of cardiomyocyte biomanufacturing
用于心肌细胞生物制造质量控制的无标记单细胞成像
  • 批准号:
    10675976
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
A Multi-Omics Approach to Discover Metabolic Critical Quality Attributes for Cardiomyocyte Biomanufacturing
发现心肌细胞生物制造代谢关键质量属性的多组学方法
  • 批准号:
    10435467
  • 财政年份:
    2019
  • 资助金额:
    $ 33.14万
  • 项目类别:
Mechanisms of Shear Induction of Blood-Brain Barrier Phenotypes in Human iPSC-derived Brain Endothelial Progenitors
人 iPSC 来源的脑内皮祖细胞血脑屏障表型的剪切诱导机制
  • 批准号:
    10328223
  • 财政年份:
    2019
  • 资助金额:
    $ 33.14万
  • 项目类别:
A Multi-Omics Approach to Discover Metabolic Critical Quality Attributes for Cardiomyocyte Biomanufacturing
发现心肌细胞生物制造代谢关键质量属性的多组学方法
  • 批准号:
    10218267
  • 财政年份:
    2019
  • 资助金额:
    $ 33.14万
  • 项目类别:
Prevention of Candida biofilms by localized delivery of aurein analogues
通过局部递送金黄色素类似物预防念珠菌生物膜
  • 批准号:
    9221080
  • 财政年份:
    2016
  • 资助金额:
    $ 33.14万
  • 项目类别:
Prevention of Candida biofilms by localized delivery of aurein analogues
通过局部递送金黄色素类似物预防念珠菌生物膜
  • 批准号:
    9813824
  • 财政年份:
    2016
  • 资助金额:
    $ 33.14万
  • 项目类别:
Shear regulated differentiation of hPSCs to brain endothelial cells
hPSC 向脑内皮细胞的剪切调节分化
  • 批准号:
    8619338
  • 财政年份:
    2013
  • 资助金额:
    $ 33.14万
  • 项目类别:
Shear regulated differentiation of hPSCs to brain endothelial cells
hPSC 向脑内皮细胞的剪切调节分化
  • 批准号:
    8723321
  • 财政年份:
    2013
  • 资助金额:
    $ 33.14万
  • 项目类别:
Prevention of C. Albicans Biofilms by Beta-Peptide Release From Thin Films
通过薄膜释放 β 肽来预防白色念珠菌生物膜
  • 批准号:
    8681304
  • 财政年份:
    2011
  • 资助金额:
    $ 33.14万
  • 项目类别:
Prevention of C. Albicans Biofilms by Beta-Peptide Release From Thin Films
通过薄膜释放 β 肽来预防白色念珠菌生物膜
  • 批准号:
    8484784
  • 财政年份:
    2011
  • 资助金额:
    $ 33.14万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 33.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 33.14万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了